Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

Results from a sub-study of belantamab mafodotin as monotherapy and in combination with dostarlimab in relapsed/refractory multiple myeloma are reported. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• JEMPERLI (DOSTARLIMAB)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-03